---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-22-000058"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:54:50.675117+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74

## Summary
- Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.
- Reiterates FY 2022 revenue guidance $655-685M; non-GAAP EPS $2.10-2.25.
- Completed $720M convertible notes offering; repurchased $200M shares YTD.
- Antares Pharma acquisition contributed product sales; operating income $83.3M.
- Partner milestones: Roche Tecentriq SC met endpoints, argenx BLA for efgartigimod SC.

## SEC filing metadata
- accession: 0001159036-22-000058
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/halo-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-22-000058
- JSON: https://secwatch.observer/filing/0001159036-22-000058.json
- Plain text: https://secwatch.observer/filing/0001159036-22-000058.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue $209 million, EPS $0.44. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Revenue: $209 million
  - EPS: $0.44
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue for the third quarter was $209 million compared to $115.8 million for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.